%0 Journal Article
%T Real-World Experiences With a Direct-Acting Antiviral Agent for Patients With Hepatitis C Virus Infection
%A Amandeep Sahota
%A Beshoy T Yanny
%A Derenik Gharibian
%A Nyan L Latt
%A Rasham Mittal
%A T Craig Cheetham
%A Vincent Louie
%A Zoe Bider-Canfield
%J Archive of "The Permanente Journal".
%D 2017
%R 10.7812/TPP/16-096
%X Traditional hepatitis C virus treatment was limited by low cure rates, side effects, and stringent monitoring requirements. Sofosbuvir, a direct-acting antiviral agent with a cure rate of 96%, was introduced in 2013. However, trials frequently excluded patients with advanced liver disease and prior treatment experience. This study aims to elucidate the real-world cure rates and sofosbuvir safety profile
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378486/